Swiss firm forms Strategy and Development committees
Debiopharm Group, a Switzerland-based global biopharmaceutical group focused on oncology therapies, has appointed a number of management figures to key positions.
The company has created a Strategy Committee and a Development Committee, which will optimise the development stages of Debiopharm\'s products.
Kamel Besseghir, who joined Debiopharm in 1995 and has been successfully heading Debiopharm SA as chief executive since 2006, will chair both committees, starting 1 January 2012.
From that date, Bertrand Ducrey, currently ceo of Debio RP (Martigny), will succeed Besseghir. Ducrey was appointed general manager of Debio RP in 2004 before being appointed ceo in 2006.
Ducrey\'s current responsibilities as chief executive of Debio RP will go to Cedric Sager. Sager joined Debio RP in 2001. He held various positions within the company before being appointed manufacturing director in 2004 and has assisted the ceo with various responsibilities since 2007.
‘One of the main tasks of the individuals we have appointed to these key positions will be to put in place Debiopharm\'s flagship project to bring down costs and reduce the development period of our drugs while maintaining our extremely rigorous standards in respect of quality,’ said Rolland-Yves Mauvernay, founder and president of Debiopharm Group.